Login / Signup

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.

Caicun ZhouBenjamin SolomonHerbert Ho-Fung LoongKeunchil ParkMaurice PérolEdurne ArriolaSilvia NovelloBaohui HanJianying ZhouAndrea ArdizzoniM Perez MakFernando C SantiniYasir Y ElaminAlexander DrilonJürgen WolfNalin PayakachatMinji K UhDeborah RajakumarHongmei HanTarun PuriVictoria SoldatenkovaA Bence LinBoris K LinKoichi Gotonull null
Published in: The New England journal of medicine (2023)
fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov number, NCT04194944.).
Keyphrases
  • advanced non small cell lung cancer
  • small cell lung cancer
  • epidermal growth factor receptor
  • brain metastases
  • locally advanced
  • radiation therapy